Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) saw a large drop in short interest in May. As of May 15th, there was short interest totaling 368,665 shares, a drop of 42.8% from the April 30th total of 644,870 shares. Based on an average daily trading volume, of 1,050,694 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.7% of the shares of the company are short sold.

Hedge Funds Weigh In On Biorestorative Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC increased its holdings in Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after buying an additional 12,319 shares during the last quarter. Citadel Advisors LLC purchased a new stake in shares of Biorestorative Therapies in the 3rd quarter worth $152,000. Finally, DRW Securities LLC bought a new position in Biorestorative Therapies in the 4th quarter worth $55,000. Hedge funds and other institutional investors own 69.38% of the company’s stock.

Biorestorative Therapies Stock Performance

Shares of NASDAQ BRTX traded up $0.01 during midday trading on Thursday, hitting $0.35. 261,615 shares of the stock traded hands, compared to its average volume of 11,483,232. The firm has a market capitalization of $8.94 million, a P/E ratio of -0.33 and a beta of 0.67. Biorestorative Therapies has a one year low of $0.16 and a one year high of $2.05. The firm has a 50-day moving average of $0.26 and a two-hundred day moving average of $0.64.

Biorestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.31 million. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%. Equities analysts forecast that Biorestorative Therapies will post -0.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Biorestorative Therapies currently has a consensus rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.